Abstract
Aerosol delivery of asthma medications maximizes local effects in the lung and minimizes systemic effects compared with oral therapy. Both corticosteroids and bronchodilators are available in a variety of delivery devices for the treatment of asthma. The 1987 Montreal protocol requiring the phasing out of the chlorofluorocarbon (CFC) propellant in commonly used pressurized metered-dose inhalers (pMDIs) provided an impetus for the development of new technologies for the delivery of inhaled asthma medications. For pMDIs, CFC has been replaced with hydrofluoroalkane (HFA) propellant. New types of dry powder inhalers (DPIs) and nebulizers, aerosol delivery devices that do not use propellants, also have been introduced. Drug delivery varies based on the device type, the product formulation and patient-related factors. Thus, drug delivery can differ when the same medication is delivered via an HFA pMDI, a CFC pMDI, a DPI or a nebulizer. Even among the same type of device (eg. DPIs, pMDIs), inhaler designs and drug formulations differ. Drug and device selection should be based on consideration of the patients ability to use the device properly, the availability of a desired drug or drugs (ie. maintenance and rescue) in a particular inhaler device and patient preference. This review describes key characteristics for each device type, explains differences in markers of lung deposition, lists potential advantages and disadvantages of the different devices and discusses how these and other factors need to be considered when selecting an inhaler device that meets the individual needs of a patient.
Keywords: aerosol devices, asthma therapy, pMDI, MDI, HFA, nebulizers
Current Drug Delivery
Title: Aerosol Devices and Asthma Therapy
Volume: 6 Issue: 1
Author(s): William Berger
Affiliation:
Keywords: aerosol devices, asthma therapy, pMDI, MDI, HFA, nebulizers
Abstract: Aerosol delivery of asthma medications maximizes local effects in the lung and minimizes systemic effects compared with oral therapy. Both corticosteroids and bronchodilators are available in a variety of delivery devices for the treatment of asthma. The 1987 Montreal protocol requiring the phasing out of the chlorofluorocarbon (CFC) propellant in commonly used pressurized metered-dose inhalers (pMDIs) provided an impetus for the development of new technologies for the delivery of inhaled asthma medications. For pMDIs, CFC has been replaced with hydrofluoroalkane (HFA) propellant. New types of dry powder inhalers (DPIs) and nebulizers, aerosol delivery devices that do not use propellants, also have been introduced. Drug delivery varies based on the device type, the product formulation and patient-related factors. Thus, drug delivery can differ when the same medication is delivered via an HFA pMDI, a CFC pMDI, a DPI or a nebulizer. Even among the same type of device (eg. DPIs, pMDIs), inhaler designs and drug formulations differ. Drug and device selection should be based on consideration of the patients ability to use the device properly, the availability of a desired drug or drugs (ie. maintenance and rescue) in a particular inhaler device and patient preference. This review describes key characteristics for each device type, explains differences in markers of lung deposition, lists potential advantages and disadvantages of the different devices and discusses how these and other factors need to be considered when selecting an inhaler device that meets the individual needs of a patient.
Export Options
About this article
Cite this article as:
Berger William, Aerosol Devices and Asthma Therapy, Current Drug Delivery 2009; 6 (1) . https://dx.doi.org/10.2174/156720109787048203
DOI https://dx.doi.org/10.2174/156720109787048203 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Combination Therapeutic Approach for Asthma and Allergic Rhinitis
Current Clinical Pharmacology Alstrom Syndrome: Genetics and Clinical Overview
Current Genomics Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate
Recent Patents on Inflammation & Allergy Drug Discovery Controlled Drug Delivery Using Microdevices
Current Pharmaceutical Biotechnology Silver Based Materials for Biomedical Applications
Current Organic Chemistry Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Electrochemical Oxidation of Prednisolone at Glassy Carbon Electrode and Its Quantitative Determination in Human Serum and Tablets by Osteryoung Square Wave Voltammetry
Current Analytical Chemistry Glycosaminoglycans and the Regulation of Allergic Inflammation
Current Drug Targets - Inflammation & Allergy Ascaris lumbricoides: An Overview of Therapeutic Targets
Infectious Disorders - Drug Targets Targeting Interleukin-21 in Immune-Mediated Pathologies
Current Drug Targets The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered- Dose Inhaler in the Treatment of COVID-19 Patients
Recent Advances in Drug Delivery and Formulation Immunotoxicity of Metal Oxide and Metal Nanoparticles and Animal Models to Evaluate Immunotoxicity of Nanoparticles
Current Bionanotechnology (Discontinued) Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Small Molecule Inhibitors of PKCθ as Potential Antiinflammatory Therapeutics
Current Topics in Medicinal Chemistry PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Lack of Data on Depression-like States and Antidepressant Pharmacotherapy in Patients with Epilepsy: Randomised Controlled Trials are Badly Needed
Current Pharmaceutical Design From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued)